Explore

Trendline Trendline
Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting

Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting
Trendline Trendline
Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations

Kivu Bioscience Names Mohit Trikha as CEO to Drive Oncology Innovations
Trendline Trendline
San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development

San Diego Startup Neomorph Secures $100M for Cancer Drug Development
Trendline Trendline
San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development

San Diego Startup Neomorph Secures $100 Million Investment for Cancer Drug Development
Trendline Trendline
Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment

Adcendo Secures $75 Million to Advance Antibody-Drug Conjugate Pipeline for Cancer Treatment
Trendline Trendline
Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting

Iterion Therapeutics Presents New Data on Tegavivint for Wnt-Driven Cancers at AACR Meeting
Trendline Trendline
BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial

BioNTech and DualityBio Report Promising Results in Mid-Stage Endometrial Cancer Trial
Trendline Trendline
IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy

IDEAYA and Servier's Eye Cancer Drug Advances to FDA with Promising Efficacy
Trendline Trendline
Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment

Vir Biotechnology Begins Phase 1 Expansion for Prostate Cancer Treatment
Trendline Trendline
IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial

IDEAYA Biosciences to Reveal Topline Results from Uveal Melanoma Trial
Trendline Trendline
Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development

Eli Lilly to Acquire CrossBridge Bio to Enhance Antibody-Drug Conjugate Development
Trendline Trendline
IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma

IDEAYA Biosciences to Reveal Phase 2/3 Trial Results for Metastatic Uveal Melanoma